Chinese VC alliance to back early-stage bio-ventures

A variety of public and private venture groups in China have created a loosely structured association that will back early-stage biotech ventures. Companies such as Shijiazhuang Pharmaceutical Group, DSM China and the Chinese Academy of Sciences plan to raise $145 million in the near term. And much of that money will be earmarked for biopharmaceuticals, biomaterials and industrial enzymes.

- read the report from China Bio Today

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.